White paper2026-10-10
GLP-1 Digital Care and Companion Platforms: What Drives Results—and Why Patients Discontinue
Summary: In this white paper, we examine what helps people achieve lasting results with GLP-1-based treatments and why many discontinue. We explore how medication access, affordability, side effects, clinical follow-up, and everyday support shape the treatment journey. We also review evidence linking digital engagement with better weight-loss outcomes, while distinguishing association from causation. We outline how digital care and companion platforms can support continuity through self-monitoring, lifestyle support, and planned follow-up when treatment changes or stops. Within this framework, we describe SALUNOTE’s role as a non-clinical companion for everyday habits and personal records, with medical decisions remaining with each person’s clinician. The evidence reviewed informs this approach; it does not establish clinical outcomes for SALUNOTE itself.